125 related articles for article (PubMed ID: 11707681)
1. Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Meroni L; Manganaro D; Varchetta S; Gatti N; Riva A; Monforte AD; Galli M
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):401-3. PubMed ID: 11707681
[No Abstract] [Full Text] [Related]
2. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
3. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection.
Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H
J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA.
Kaufmann GR; Zaunders JJ; Cunningham P; Cooper DA
AIDS Res Hum Retroviruses; 1999 Jul; 15(11):963-72. PubMed ID: 10445808
[TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M
AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852
[TBL] [Abstract][Full Text] [Related]
6. Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H; Stürner KH; Höhn C; Braun P
HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy.
Viganó A; Saresella M; Rusconi S; Ferrante P; Clerici M
Lancet; 1998 Dec; 352(9144):1905-6. PubMed ID: 9863793
[No Abstract] [Full Text] [Related]
8. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection.
Orendi JM; Bloem AC; Borleffs JC; Wijnholds FJ; de Vos NM; Nottet HS; Visser MR; Snippe H; Verhoef J; Boucher CA
J Infect Dis; 1998 Nov; 178(5):1279-87. PubMed ID: 9780247
[TBL] [Abstract][Full Text] [Related]
9. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
[TBL] [Abstract][Full Text] [Related]
10. Limited immune reconstitution at intermediate stages of HIV-1 infection during one year of highly active antiretroviral therapy in antiretroviral-naive versus non-naive adults.
Martín M; Echevarría S; Leyva-Cobián F; Pereda I; López-Hoyos M
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):871-9. PubMed ID: 11837638
[TBL] [Abstract][Full Text] [Related]
11. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation.
Cohen Stuart JW; Hazebergh MD; Hamann D; Otto SA; Borleffs JC; Miedema F; Boucher CA; de Boer RJ
J Acquir Immune Defic Syndr; 2000 Nov; 25(3):203-11. PubMed ID: 11115950
[TBL] [Abstract][Full Text] [Related]
12. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.
Liu Z; Cumberland WG; Hultin LE; Kaplan AH; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):332-40. PubMed ID: 9704938
[TBL] [Abstract][Full Text] [Related]
13. Cd4+ T cells programmed to traffic to lymph nodes account for increases in numbers of cd4+ T cells up to 1 year after the initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection.
Hengel RL; Jones BM; Kennedy MS; Hubbard MR; McDougal JS
J Infect Dis; 2001 Jul; 184(1):93-7. PubMed ID: 11398115
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.
Larsen CS; Ostergård L; Møller BK; Buhl MR
Scand J Infect Dis; 2000; 32(2):153-60. PubMed ID: 10826900
[TBL] [Abstract][Full Text] [Related]
15. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy.
Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
Kelleher AD; Carr A; Zaunders J; Cooper DA
J Infect Dis; 1996 Feb; 173(2):321-9. PubMed ID: 8568292
[TBL] [Abstract][Full Text] [Related]
17. Naïve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART.
Resino S; Navarro J; Bellón JM; Gurbindo D; León JA; Muñoz-Fernández MA
Clin Exp Immunol; 2001 Aug; 125(2):266-73. PubMed ID: 11529919
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.
Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT
Clin Exp Immunol; 1999 Mar; 115(3):458-63. PubMed ID: 10193418
[TBL] [Abstract][Full Text] [Related]
19. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator.
Hultin LE; Matud JL; Giorgi JV
Cytometry; 1998 Oct; 33(2):123-32. PubMed ID: 9773872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
